Nocebo Effect in Randomized Clinical Trials of Antidepressants in Children and Adolescents: Systematic Review and Meta-Analysis

View/ Open
Author
Rojas-Mirquez, Johanna Carolina
Rodriguez-Zuñiga, Milton Jose Max
Bonilla-Escobar, Francisco Javier
Garcia-Perdomo, Herney Andres
Petkov, Mike
Published Version
https://doi.org/10.3389/fnbeh.2014.00375Metadata
Show full item recordCitation
Rojas-Mirquez, Johanna Carolina, Milton Jose Max Rodriguez-Zuñiga, Francisco Javier Bonilla-Escobar, Herney Andres Garcia-Perdomo, Mike Petkov, Lino Becerra, David Borsook, and Clas Linnman. 2014. “Nocebo Effect in Randomized Clinical Trials of Antidepressants in Children and Adolescents: Systematic Review and Meta-Analysis.” Frontiers in Behavioral Neuroscience 8 (1): 375. doi:10.3389/fnbeh.2014.00375. http://dx.doi.org/10.3389/fnbeh.2014.00375.Abstract
Objective:: To compare the incidence of adverse events between active and placebo arms of randomized clinical trials in depressive children and adolescents (C&A) with antidepressant treatments, in order to look for similarities in both groups that allow to establish a possible nocebo effect. Methods:: Systematic search strategy (January 1974–March 2013) in electronic databases, conference abstracts, and reference list of systematic reviews and included studies to identify parallel randomized placebo-controlled trials of antidepressants in C&A (<19 years) with major depressive disorder, and one or more interventions of any orally administered antidepressant. The pooled adverse events were calculated based on a fixed-effect model and statistical analysis involved the risk ratio (RR) of adverse events, with 95% confidence intervals (95% CI). Results:: Sixteen studies were included in the review, of which seven studies with a sample of 1911 patients had data to include in the meta-analysis. There was similar risk for the incidence of adverse events between non-active and active group (global RR 1.04, 95% CI: 0.97–1.11). Conclusion:: Depressive C&A allocated to placebo or active group had similar risk to develop adverse events. These similarities in both groups are attributed to the nocebo effect. It is of note that defining “nocebo” effects is challenging in clinical populations because adverse effects may be attributed to the intervention or may be manifestation of the disease itself. The inclusion of a no-treatment arm may be warranted. Nocebo effects are likely when adverse events of placebo mimic the adverse events of active treatment, as was the case here.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217505/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:13454854
Collections
- HMS Scholarly Articles [17875]
Contact administrator regarding this item (to report mistakes or request changes)